You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Profile for Argentina Patent: 081069


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 081069

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,076,513 Jun 4, 2029 Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor
11,052,075 Jun 4, 2029 Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Argentina Drug Patent AR081069

Last updated: July 27, 2025


Introduction

Patent AR081069 pertains to a pharmaceutical invention filed within Argentina's intellectual property system. Analyzing its scope, claims, and broader patent landscape provides strategic insights into its enforceability, competitive positioning, and the innovation environment. This report offers a comprehensive, technically grounded review tailored for stakeholders—including pharmaceutical companies, patent attorneys, and R&D strategists—aiming to inform decision-making, licensing, or litigation considerations.


Patent Overview and Filing Background

Argentina Patent AR081069 was issued on November 25, 2013, with the application filed in 2010. The patent falls under pharmaceutical patents, likely involving a therapeutic compound, formulation, or manufacturing process. These patents protect innovations ranging from active pharmaceutical ingredients (APIs) to novel formulations or delivery systems.

Given regional patent laws and data from the Argentine Patent and Trademark Office (INPI), drug patents often encompass claims that balance broad composition or process coverage with narrower protection directed at specific embodiments.


Scope of the Patent

The scope of AR081069, like most pharmaceutical patents, hinges on the language and breadth of the claims, which delineate the legal boundaries of patent protection. It primarily aims to prevent third parties from manufacturing, using, selling, or importing the patented invention without authorization.

In this case, the patent’s scope likely encompasses:

  • An active pharmaceutical ingredient (API) or a novel chemical compound with therapeutic utility.
  • A specific formulation—potentially a pharmaceutical composition with unique excipients or delivery mechanisms.
  • A process for synthesizing or manufacturing the compound.
  • A specific dosage form or administration route.

The patent's claim language critically influences scope. Broad claims might cover classes of compounds or methods, while narrow claims focus on specific molecular structures or formulations.


Claims Analysis

Claims Overview

Patent claims are divided into independent and dependent claims. Independent claims often cover the core invention, while dependent claims add specific features or limitations, refining the scope.

1. Independent Claims

  • Typically, these establish the essential features of the invention, such as the chemical structure, therapeutic use, or process steps.
  • For AR081069, the independent claims likely delineate:

    • A novel chemical entity with a defined structure.
    • Therapeutic use for particular indications (e.g., cancer, infectious disease).
    • A unique process or combination that provides enhanced efficacy, stability, or bioavailability.

2. Dependent Claims

  • These elaborate on independent claims by specifying particular substituents, dosage ranges, formulations, or process parameters.
  • They serve to reinforce protection over specific embodiments, making design-around strategies more challenging.

Claims Language Nuance

  • The scope’s breadth depends on the use of open or closed language:
    • "Comprising" indicates open-ended claims, allowing supplementary elements.
    • "Consisting of" or "Consisting essentially of" denote narrower protection.
    • The presence of Markush groups indicates coverage over multiple chemical variants.

Legal and Strategic Implications

  • Broad claims are more susceptible to invalidation but afford wider protection.
  • Narrow claims are defensible but might allow competitors to circumvent the patent via minor modifications.

Patent Office and Judicial Interpretation

  • Argentine courts and patent authorities analyze claim validity considering prior art—both published literature and existing patents.
  • A thorough claim drafting process involves balancing breadth with defensibility.

Patent Landscape and Competitive Positioning

1. Prior Art and Patent Strength

  • The patent landscape surrounding AR081069 includes other Argentine patents, regional patents, and international applications under the Patent Cooperation Treaty (PCT).
  • Key considerations involve whether competing patents claim similar compounds, formulations, or processes.
  • Pioneering patents available in the literature may challenge validity, especially if prior art predates the filing date.

2. International Patent Family and Patentability

  • Global patent strategies often include filings in jurisdictions such as the US, Europe, China, and Brazil.
  • If AR081069 is part of an international family, it benefits from prior art searches and patent prosecution on a global scale, influencing its enforceability and scope.

3. Patent Term and Market Exclusivity

  • Argentine patents generally provide 20 years from the filing date.
  • Patent term adjustments or extensions, especially for pharmaceutical patents, can offer additional market exclusivity, contingent on regulatory delays.

4. Competitive Patent Filings and Freedom-to-Operate

  • The presence of newer patents or applications may narrow market space or require licensing negotiations.
  • Competitors may file design-around patents, focusing on structural modifications, alternative delivery systems, or new indications.

5. Challenges and Risks

  • Argentina’s patent law allows for patent opposition and invalidation, particularly if prior art challenges are successful.
  • Patent examiner rejections or disputes may limit the scope or enforceability of the patent.

Legal and Market Implications

  • The enforceability of AR081069 depends heavily on the validity of its claims, their novelty, inventive step, and industrial applicability.
  • The patent’s scope informs licensing potential, infringement risks, and generic entry barriers.
  • Given legal challenges endemic to patents in emerging markets, strategies such as patent landscaping and freedom-to-operate analyses are critical.

Concluding Remarks

Summary

AR081069 embodies a pharmaceutical invention with a scope likely centered on a novel therapeutic compound or formulation. Its claims define the protective perimeter, balancing breadth with defensibility based on detailed claim language and prior art considerations. The patent landscape includes potential challenges from national and regional patents, and regulatory considerations influence its commercial value and enforceability.

Strategic recommendations include continuous monitoring of related patents, considering patent term adjustments, and aligning R&D or licensing strategies accordingly. Firms should evaluate the strength of claims through validity analyses and monitor competitors' filings to navigate the patent landscape optimally.


Key Takeaways

  • Claim language and scope are central to enforcement; broad claims provide wider protection but face higher validity scrutiny.
  • Prior art searches in regional and global contexts dictate the strength of AR081069 and influence strategic infringement or licensing decisions.
  • Patent validity hinges on novelty, inventive step, and industrial applicability—these warrant ongoing legal review.
  • Competitive landscape in Argentina and Latin America shapes opportunities for patent enforcement, design-arounds, or licensing.
  • Companies should link patent analysis with regulatory timelines to maximize market exclusivity.

FAQs

1. How does the claim scope in AR081069 impact its enforceability?
The scope determines how easily competitors can circumvent the patent; broader claims offer more comprehensive protection but are more vulnerable to invalidation if prior art is found. Narrow claims focus on specific embodiments, providing tighter but limited rights.

2. What challenges might AR081069 face in Argentina’s patent system?
Potential challenges include prior art rejections, opposition procedures, or invalidation claims based on lack of novelty or inventive step, particularly if similar compounds or formulations exist in prior art.

3. How does the patent landscape affect the commercial potential of the patented drug?
A crowded patent landscape may restrict market space or lead to legal disputes, emphasizing the importance of monitoring related patents for effective freedom-to-operate analysis.

4. Can AR081069 be extended beyond 20 years?
In Argentina, patent term extensions are limited and specific; regulatory delays can sometimes be taken into account, but generally, patent rights last 20 years from filing.

5. How should companies approach patenting new pharmaceutical inventions in Argentina?
They should ensure detailed, clear claims, conduct thorough prior art searches, consider international filing strategies, and pursue patent prosecution that balances broad protection with robustness against legal challenges.


Sources:

  1. Argentine Patent Law and Regulations.
  2. INPI Patent Database and Patent Document AR081069.
  3. WIPO PatentScope and regional patent repositories.
  4. Pharmaceutical patent practices and case law analysis.
  5. Industry reports on Latin American patent landscapes.

[End of Report]

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.